Institute of Medical Biology
A*STAR

# Seminar Announcement

***- All Are Welcome -***



**Speaker:** **Prof Bin Tean TEH**

Deputy Director (Research), National Cancer Centre, Singapore
Deputy Director (Scientific), SingHealth/Duke-NUS Institute of Precision Medicine
Professor, Duke-NUS Medical School, Singapore
Senior Principal Investigator, Cancer Science Institute, Singapore
Senior Principal Investigator, Institute of Molecular and Cell Biology, Singapore

**Title :** ***"Asian Cancer Genomics And Its Clinical Implications"***

**Date :** **7 Feb 2017 (Tuesday)**
**Time :** **11.00pm – 12.00pm**
**Venue :** **Creation Theatrette, Matrix Level 4, Biopolis**
**Host :** **Prof Maurice van Steensel**
(Tel: 6407 0191, email: maurice.vansteensel@imb.a-star.edu.sg)

*** Prof Teh is available for meet ups from 12pm to 2pm.**

***Abstract of the Seminar:***

Our works focus on the genomic profiling of Asian-centric cancers using high-throughput technologies and the data is correlated with clinicopathological information. The goals are to 1) understand the molecular mechanism underlying these cancers; and 2) to identify potential therapeutic targets and novel biomarkers related to the behavior of the disease. In this talk, I will first present our recent genomic studies of the fibroepithelial tumors of the breast, from the very common benign fibroadenoma to the rare but malignant Phyllodes tumors. Several frequently mutated genes such as MED12 and RARA will be highlighted and discussed. Second, I will describe our works on cholangiocarcinoma (biliary tract cancer) including cases related to liver fluke infection. There is significant difference in the spectrum and frequency of the alterations between fluke-related and non-fluke related cases, explaining the difference in their underlying pathogenesis. Third, I will describe our recent discovery of the molecular fingerprint of a herbal carcinogen called Aristolochic Acid, which is associated with upper urinary tract urothelial cancer. This discovery not only enhances our understanding of the molecular mechanism of this carcinogen, but allows screening for the involvement of this carcinogen in other cancer types such as liver cancer.

***About the Speaker:***

Dr Teh obtained his MD (1992) from the University of Queensland, Australia and his PhD (1997) from the Karolinska Institute, Sweden. Following postdoctoral works at Karolinska Institute, he joined the Van Andel Research Institute (VARI), USA in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. From 2003, he served as the Deputy Director (Research Operations) of VARI and from 2008, Director of VARI International. He established the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010 he received the Singapore Translational Research Investigator Award and relocated to Singapore. He served as the SingHealth Group Director for Translational Research from 2010-2012. His laboratory focuses on Asian Cancer Genomics and in the last 5 years have made seminal discoveries in the field including biliary tract cancer, urological cancer and breast tumors. He holds Adjunct Professorships at several universities worldwide including Baylor College of Medicine, USA, Nanjing University and Sun Yat-Sen University, China and the Karolinska Institute, Sweden. Dr. Teh has published extensively, with over 350 publications (author h-index: 65). He is a past and present member of numerous editorial boards for journals including Lancet Oncology, Cancer Research, Molecular Cancer Therapeutics. Dr Teh is a recipient of the 2015 Singhealth Distinguished Researcher Award and co-recipient of the 2015 Singapore President Science Award.